Edition:
India

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

16.70USD
19 Jan 2018
Change (% chg)

$-0.02 (-0.12%)
Prev Close
$16.72
Open
$16.73
Day's High
$16.84
Day's Low
$16.20
Volume
202,520
Avg. Vol
226,418
52-wk High
$27.07
52-wk Low
$8.73

Chart for

About

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria... (more)

Overall

Beta: 3.62
Market Cap(Mil.): $1,019.17
Shares Outstanding(Mil.): 47.45
Dividend: --
Yield (%): --

Financials

BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy

* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY

03 Jan 2018

BRIEF-Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients

* OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS

12 Dec 2017

BRIEF-Omeros Corp reports Q3 loss per share $0.16

* Omeros Corporation reports third quarter 2017 financial results

10 Nov 2017

BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721

* OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

26 Oct 2017

BRIEF-Omeros Corp amends term loan agreement

* On Oct 11, co entered amendment no. 1 to loan agreement, which amended term loan agreement, dated October 26, 2016​

17 Oct 2017

BRIEF-OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

* OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

05 Oct 2017

BRIEF-Omeros announces pricing of public offering of common stock

* Omeros announces pricing of public offering of common stock

15 Aug 2017

BRIEF-Omeros announces public offering of common stock

* Says offering 3.00 million common shares Source text for Eikon: Further company coverage:

15 Aug 2017

BRIEF-Omeros Corporation Q2 loss per share $0.33

* Omeros corporation reports second quarter 2017 financial results

09 Aug 2017

BRIEF-FDA grants orphan drug designation to Omeros’ OMS721

* FDA grants Orphan Drug Designation to Omeros’ OMS721 for treatment of IGA Nephropathy

04 Aug 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $147.36 +0.44
Novartis AG (NOVN.S) CHF83.38 +0.48
Pfizer Inc. (PFE.N) $36.94 -0.05
Roche Holding Ltd. (ROG.S) CHF234.50 +1.30
Roche Holding Ltd. (RO.S) CHF237.80 +1.00
Merck & Co., Inc. (MRK.N) $61.28 +0.15
Bayer AG (BAYGn.DE) €104.08 +0.60
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €72.95 +0.58
Eli Lilly and Co (LLY.N) $85.49 -0.33

Earnings vs. Estimates